• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agios Pharmaceuticals, Inc. - Common Stock (NQ:AGIO)

37.39 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agios Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
What's going on in today's pre-market session ↗
August 04, 2025
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
August 04, 2025
 
Via Benzinga
News headline image
Agios (AGIO) Q2 Revenue Jumps 45% ↗
August 01, 2025
Via The Motley Fool
Topics Intellectual Property
News headline image
Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Mixed Q2 2025 Results: Revenue Beat but Wider EPS Loss ↗
July 31, 2025
Agios Pharmaceuticals (AGIO) reported Q2 2025 revenue of $12.46M, beating estimates, but EPS of -$1.93 missed forecasts. Shares fell 10.66% pre-market amid mixed financials and ongoing rare disease... 
Via Chartmill
News headline image
Earnings Scheduled For July 31, 2025 ↗
July 31, 2025
 
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
May 01, 2025
 
Via Benzinga
News headline image
An Overview of Agios Pharmaceuticals's Earnings ↗
April 30, 2025
 
Via Benzinga
News headline image
Earnings Scheduled For February 13, 2025 ↗
February 13, 2025
 
Via Benzinga
News headline image
Analyst Ratings For Agios Pharmaceuticals ↗
December 10, 2024
 
Via Benzinga
News headline image
Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years ↗
February 13, 2025
Agios' mitapivat met its primary endpoint in a Phase 3 trial for PK deficiency in children. The company plans a marketing application based on the results. 
Via Benzinga
News headline image
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday ↗
December 16, 2024
 
Via Benzinga
News headline image
Agios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' Drug ↗
December 09, 2024
The company is currently seeking approval for its thalassemia treatment in four regions. 
Via Investor's Business Daily
News headline image
Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗
November 01, 2024
 
Via Benzinga
News headline image
Earnings Preview: Agios Pharmaceuticals ↗
October 30, 2024
 
Via Benzinga
News headline image
4 Analysts Have This To Say About Agios Pharmaceuticals ↗
October 10, 2024
 
Via Benzinga
News headline image
Expert Ratings For Agios Pharmaceuticals ↗
June 17, 2024
 
Via Benzinga
News headline image
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
September 27, 2024
 
Via Benzinga
News headline image
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday ↗
September 27, 2024
 
Via Benzinga
News headline image
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗
September 26, 2024
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
News headline image
Agios Pharmaceuticals' Rare Blood Disorder Drug Misses Primary Goal In Pediatric Study, Stock Slides ↗
August 01, 2024
Agios Pharmaceuticals' Phase 3 ACTIVATE-KidsT study results reveal that mitapivat achieved a 28.1% transfusion reduction in children with PK deficiency compared to 11.8% with placebo. Secondary... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
June 13, 2024
 
Via Benzinga
News headline image
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio? ↗
June 09, 2024
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
Via Benzinga
News headline image
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge ↗
June 05, 2024
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024. 
Via InvestorPlace
News headline image
Why Is Agios Pharmaceuticals Stock Trading Higher On Monday? ↗
June 03, 2024
Agios Pharmaceuticals shares rose after it announced its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved the primary endpoint of... 
Via Benzinga
News headline image
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
June 03, 2024
 
Via Benzinga
News headline image
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
May 28, 2024
 
Via Benzinga
News headline image
Nvidia Again Boosts Nasdaq To Record Highs ↗
May 28, 2024
The Nasdaq Composite Index is extending Friday's record highs, with help from Nvidia, which is up 5% at last glance and marking its own all-time highs. 
Via Talk Markets
Topics Stocks
News headline image
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday? ↗
May 28, 2024
Agios Pharmaceuticals sells its 15% royalty rights on U.S. net sales of Servier's vorasidenib to Royalty Pharma for $905 million upon FDA approval. 
Via Benzinga
News headline image
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
May 28, 2024
 
Via Benzinga
News headline image
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out ↗
May 28, 2024
The stock is poised to break out of a cup-with-handle base after inking a deal for a cancer drug. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap